Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER)

• Status: Completed
• Trial end date: 2014-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is crossover study to evaluate safety and efficacy of lansoprazole in preterm infants with gastroesophageal reflux.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Dexlansoprazole; Lansoprazole

Criteria

Inclusion Criteria:

• preterm infant

• symptoms suspecting gastroesophageal reflux

Exclusion Criteria:

• unstable general conditions due infection or acute illness

• congenital anomaly in upper gastrointestinal tract including esophagus

• drug history of H2, proton pump inhibitor, blocker during last 1 week

• medication of warfarin, carbamazepine, phenytoin, rifampin

• inappropriate clinical conditions judged by researchers